Clinical Trial Update: JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial update: JAB-21822 in combination with JAB-3312 versus standard of care in first-line treatment of advanced non-small cell lung cancer with KRAS p.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JAB-21822
• JAB-3312

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING